Document is current

Article History

Received: 12 February 2024

Accepted: 18 September 2024

First Online: 1 November 2024

Declarations

:

: Boulos Haraoui has received grants and honoraria from AbbVie, Amgen, Eli Lilly, Gilead Sciences, Janssen, Pfizer Inc and UCB. Majed Khraishi has received honoraria from AbbVie, Amgen, Celgene, Eli Lilly, Novartis, Pfizer Inc and UCB. Denis Choquette has received grants and honoraria from AbbVie, Amgen, CIHR, Eli Lilly, Fresenius Kabi, Novartis, Pfizer Inc, Sandoz, Teva Pharmaceuticals and Viatris. Isabelle Fortin has received honoraria for research and continuing medical education from AbbVie, Amgen, Eli Lilly, Novartis, Pfizer Inc and UCB. Cassandra D Kinch was an employee and shareholder of Pfizer Inc at the time of the analysis. Corina Galos was an employee and shareholder of Pfizer Inc at the time of the analysis. Patrice Roy was an employee and shareholder of Pfizer Inc at the time of the analysis, but is now affiliated with G.I.S. Conseils Inc. David Gruben is an employee and shareholder of Pfizer Inc. Julie Vaillancourt and John S Sampalis are employees of JSS Medical Research Inc., which was a paid consultant to Pfizer in connection with the study development, management, conduct, data collection, data analysis and medical writing, including the development of the manuscript. Edward C Keystone was affiliated with the University of Toronto at the time of this study, but has since retired; he received grants and/or research support from Amgen, Merck, Pfizer Inc and PuraPharm, has acted as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celltrion, Eli Lilly, F Hoffmann-La Roche, Gilead Sciences, Janssen, Merck, Myriad Autoimmune, Pfizer Inc, Samsung Bioepsis, Sandoz and Sanofi Genzyme and has received speaker fees or honoraria from AbbVie, Amgen, F. Hoffman-La Roche, Janssen, Merck, Novartis, Pfizer Inc and Sanofi Genzyme. Edward C Keystone was an Editorial Board member of <i>Rheumatology and Therapy</i> at the time of publication; however, he was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.

: CANTORAL was conducted in compliance with the Declaration of Helsinki, International Council for Harmonisation Guidelines for Good Clinical Practice and local country regulations. The study protocol was approved by Advarra (MOD00903929) and the Institutional Review Board or Independent Ethics Committee at each centre as per institutional/clinical requirements. Patients provided written informed consent.